Phase II study of sorafenib (NSC-724772) and erlotinib (NSC-718781) in patients with advanced gallbladder carcinoma or cholangiocarcinoma

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT01093222?term=S0941&rank=1

2. Intervention

   Erlotinib hydrochloride

3. Intervention

   Sorafenib tosylate

4. Additional Topic(s)

   Antineoplastic combined chemotherapy protocols

5. Resource Description

   RATIONALE: Sorafenib tosylate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma.

6. Contact

   Berenberg, Jeffrey

7. PI

   Berenberg, Jeffrey

8. Topic

   gallbladder cancer

9. Study Population

   Males and females from age 18 Years and older are eligible.

10. Funded by

    SWOG

11. Phase

    Phase 2 clinical trial

12. Performed by

    Clinical Protocol & Data Management Shared Resource